IL-17 Antagonists as a Promising Therapeutic Modality for Hidradenitis Suppurativa

References

1. Sabat R. Jemec G.B.E. Matusiak Ł. Kimball A.B. Prens E. Wolk K. Hidradenitis suppurativa. Nat. Rev. Dis. Primers 2020 6 1 18 10.1038/s41572‑020‑0149‑1 32165620
   [Google Scholar]
2. Krajewski P.K. Matusiak Ł. von Stebut E. Quality-of-life impairment among patients with hidradenitis suppurativa: A cross-sectional study of 1795 patients. Life 2021 11 1 34 10.3390/life11010034 33429896
   [Google Scholar]
3. Matusiak Ł. Profound consequences of hidradenitis suppurativa: A review. Br. J. Dermatol. 2020 183 6 e171 e177 10.1111/bjd.16603 29744872
   [Google Scholar]
4. Zouboulis C.C. Desai N. Emtestam L. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J. Eur. Acad. Dermatol. Venereol. 2015 29 4 619 644 10.1111/jdv.12966 25640693
   [Google Scholar]
5. Schlapbach C. Hänni T. Yawalkar N. Hunger R.E. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J. Am. Acad. Dermatol. 2011 65 4 790 798 10.1016/j.jaad.2010.07.010 21641076
   [Google Scholar]
6. Wolk K. Warszawska K. Hoeflich C. Deficiency of IL-22 contributes to a chronic inflammatory disease: Pathogenetic mechanisms in acne inversa. J. Immunol. 2011 186 2 1228 1239 10.4049/jimmunol.0903907 21148041
   [Google Scholar]
7. Sabat R. Gudjonsson J.E. Brembilla N.C. van Straalen K.R. Wolk K. Biology of interleukin-17 and novel therapies for hidradenitis suppurativa. J. Interferon Cytokine Res. 2023 43 12 544 556 10.1089/jir.2023.0105 37824200
   [Google Scholar]
8. Matusiak Ł. Szczęch J. Bieniek A. Nowicka-Suszko D. Szepietowski J.C. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents. J. Am. Acad. Dermatol. 2017 76 4 670 675 10.1016/j.jaad.2016.10.042 28041632
   [Google Scholar]
9. Kimball A.B. Jemec G.B.E. Alavi A. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): Week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet 2023 401 10378 747 761 10.1016/S0140‑6736(23)00022‑3 36746171
   [Google Scholar]
10. Kimball A.B. Jemec G.B.E. Sayed C.J. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): Two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet 2024 403 10443 2504 2519 10.1016/S0140‑6736(24)00101‑6 38795716
    [Google Scholar]
11. Glatt S. Jemec G.B.E. Forman S. Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa. JAMA Dermatol. 2021 157 11 1279 1288 10.1001/jamadermatol.2021.2905 34406364
    [Google Scholar]
12. ACELYRIN, INC. Announces top-line results from placebo-controlled clinical trial of izokibep for moderate-to-severe hidradenitis suppurativa. 2023 Available from: https://www.biospace.com/article/releases/acelyrin-inc-announces-top-line-results-from-placebo-controlled-clinical-trial-of-izokibep-for-moderate-to-severe-hidradenitis-suppurativa/
    [Google Scholar]
13. MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa. 2023 Available from: https://ir.moonlaketx.com/news-releases/news-release-details/moonlake-immunotherapeutics-achieves-landmark-milestone-positive
14. Osorio-Gómez G.F. Ortiz-Álvarez J. Diaz-Ceca D. Guijarro-Sánchez C. Conejo-Mir Sánchez J. Fernández Crehuet P. Brodalumab for moderate–severe hidradenitis suppurativa: An open‐label multicentric cohort study in real clinical practice. Australas. J. Dermatol. 2024 65 3 254 259 10.1111/ajd.14267 38597096
    [Google Scholar]
15. Gao J.L. Otto T.S. Porter M.L. Kimball A.B. Hidradenitis suppurativa: New targets and emerging treatments. Am. J. Clin. Dermatol. 2024 25 5 765 778 10.1007/s40257‑024‑00880‑1 39060744
    [Google Scholar]